An elderly man with a white beard and hair, wearing a denim jacket, is smiling and waving from the driver's seat of a blue car.

See tomorrow.

Blindness shouldn’t be inevitable—we need personalized treatments that preserve sight.

At OcularDx we are transforming ophthalmic drug development and treatment outcomes through molecular profiling, AI-driven analytics, and the world’s first vitreous biorepository—introducing precision ophthalmology.

The vitreous contains billions of extracellular vesicles… including measurable therapeutic targets.

These vesicles carry protected molecular cargo - proteins, RNA, and DNA that serve as real-time biomarkers of retinal disease​.

Until now, this vital fluid has remained inaccessible for routine analysis.

Ophthalmology’s Blind Spot

Precision medicine has transformed patient care and outcomes across most therapeutic areas, yet ophthalmology has been left behind. The consequences: delayed innovation, costly clinical trial failures, and a one-size-fits-all approach to treatment.

Anti-VEGF therapies leave >50% of patients as partial or non-responders

Disease detection and treatment management rely heavily on structural and functional read-outs, not molecular evidence.

Clinical trials lack molecular stratification, leading to costly late-stage development failures.

Our Technology

Our patented vitreous biopsy device* is a single-use handheld device designed to collect undiluted vitreous without a console, foot pedal, or tubing.

*The OcularDx vitreous biopsy device is not cleared by the U.S. FDA for human use.

  • Designed to collect undiluted vitreous within a standard clinical workflow.

  • Proteomics, metabolomics, and vesicle profiling from each sample

  • Purpose-built for reproducible sampling across study sites.

Available Now for Program Sponsors

OcularDx is taking a limited number of strategic engagements to support pre-clinical programs. To discuss fit, contact us.

For pharmaceutical partners, we generate molecular evidence to support:

  • Go/no-go decisions based on target engagement

  • Dose selection grounded in drug exposure at the site of action

  • Responder hypotheses and patient stratification

  • Post-hoc analysis of pathway activation

Two middle-aged women smiling and looking at a smartphone outdoors in a park.

For patients, our mission is to enable:

  • Earlier intervention, before irreversible vision loss

  • Matched therapies that maximize treatment response

  • Reduced injection burden through optimized regimens

  • Access to breakthrough therapies that restore vision

We are scientists who have dedicated decades to unlocking the molecular language of the eye, pioneering and proving vitreous extracellular vesicles as a revolutionary biomarker source because we believe sight-saving precision care should be available to everyone.

Logo with a stylized eye and circuit-like patterns containing the text 'OcularDx' in dark blue with 'Dx' in light blue.
  • A black and white portrait of a man in a suit, looking slightly to the side.

    Alan Wright MD, MPH

    CEO

    Dr. Wright is the former CMO Roche Diagnostics & BioMérieux North America.

  • Black and white portrait of a smiling man with short hair and a beard, wearing a suit jacket and white shirt against a dark background.

    Jeff Sundstrom MD, PhD

    Chief Scientist

    Dr. Sundstrom is the proteomics and extracellular vesicle diagnostics pioneer at UPenn Scheie Eye Institute; author of 40+ peer-reviewed publications.

  • Black and white photo of a man in a white medical coat with a University of Michigan logo, wearing glasses and a tie, smiling.

    Thomas Gardner MD

    Chairman of the Board

    Dr. Gardner is the global authority in diabetic retinal neurovascular injury; architect of the integrative staging framework for diabetic retinopathy.

Share our vision? We’d love to hear from you.

Accelerate breakthrough therapies and transform lives.